Taro Pharmaceutical Industries Ltd
F:TAL

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
F:TAL
Watchlist
Price: 40 EUR 1.01% Market Closed
Market Cap: 1.5B EUR

Taro Pharmaceutical Industries Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Taro Pharmaceutical Industries Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Taro Pharmaceutical Industries Ltd
F:TAL
Operating Income
$21.5m
CAGR 3-Years
-47%
CAGR 5-Years
-41%
CAGR 10-Years
-26%
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Operating Income
$3.8B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
-2%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Operating Income
-$10.2m
CAGR 3-Years
N/A
CAGR 5-Years
20%
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Operating Income
-₪49.3m
CAGR 3-Years
N/A
CAGR 5-Years
-74%
CAGR 10-Years
N/A
PolyPid Ltd
NASDAQ:PYPD
Operating Income
-$28m
CAGR 3-Years
13%
CAGR 5-Years
-9%
CAGR 10-Years
-23%
Mediwound Ltd
NASDAQ:MDWD
Operating Income
-$23.6m
CAGR 3-Years
-19%
CAGR 5-Years
-20%
CAGR 10-Years
-1%
No Stocks Found

Taro Pharmaceutical Industries Ltd
Glance View

Market Cap
1.5B EUR
Industry
Pharmaceuticals

In the often-underappreciated realm of generic pharmaceuticals, Taro Pharmaceutical Industries Ltd. has carved out a notable niche for itself. Founded in 1950 in Haifa, Israel, Taro's journey began with a focus on dermatological products, a specialism that continues to be at the heart of its operations. As generic drug prices have become increasingly competitive, Taro has distinguished itself through a robust portfolio that not only includes dermatology but also topical and oral medications across various therapeutic areas. The company's commitment to quality and cost-effective drug solutions stems from its strategic use of rigorous R&D efforts, channeling years of scientific expertise to bring affordable healthcare solutions to markets worldwide. In essence, Taro crafts a business model that balances operational efficiency with the nuanced complexities of pharmaceutical manufacturing and compliance. Underpinning Taro's business strategy is its prowess in generic drug manufacture, where it maximizes its revenue by capitalizing on patent expirations from mainstream pharmaceutical enterprises. With its deep understanding of regulatory frameworks and market dynamics, Taro adeptly navigates the intricate landscapes of the U.S. and international markets, leveraging its wide distribution network. The United States, being a major revenue driver, reflects Taro's prowess and its ability to quickly adapt to drug lifecycle shifts. Yet, Taro's success isn't solely attributed to scale but also to its meticulous cost management and operational synergies across its global facilities. This orchestration allows it to maintain competitive pricing while ensuring high-quality standards - a testament to its deep-rooted industry experience and strategic foresight.

TAL Intrinsic Value
Not Available

See Also

What is Taro Pharmaceutical Industries Ltd's Operating Income?
Operating Income
21.5m USD

Based on the financial report for Mar 31, 2024, Taro Pharmaceutical Industries Ltd's Operating Income amounts to 21.5m USD.

What is Taro Pharmaceutical Industries Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-26%

Over the last year, the Operating Income growth was 22%. The average annual Operating Income growth rates for Taro Pharmaceutical Industries Ltd have been -47% over the past three years , -41% over the past five years , and -26% over the past ten years .

Back to Top